For decades, the biopharma sales rep playbook has had a clear sequence: Build a territory plan, segment and prioritize HCP, and then pre-call plan before each interaction. While the pre-call plan still matters, the healthcare system has outgrown it.
More specifically, the customer most reps were trained to engage—the autonomous HCP prescriber making independent decisions in a private practice—is no longer the dominant stakeholder. Today, more HCPs practice within health systems, IDNs, and large group practices. Formulary decisions, protocol design, and patient access pathways are increasingly set above the prescriber, often by committees and governing bodies the rep may never meet. Even in community settings, prescribing is shaped by payer policies, GPO contracts, and care pathways that reps often cannot see or access.
This is why pre-call planning, on its own, is no longer sufficient. A perfectly executed call with an HCP who no longer owns sole decision-making authority may not advance account adoption or utilization. This is why an ‘account management mindset’ is necessary.
The misconception that is holding field teams back
Inside many biopharma organizations, account management continues to be treated as a specialist role, often the purview of key account managers, health system directors, and market access leads who must navigate IDNs, academic medical centers, payers, and large community practices. Such account management framing made sense ten years ago, however, in the context of today’s life sciences healthcare ecosystem, it no longer holds up.
The sales professional population is the largest customer-facing group in biopharma. Thousands of reps work across oncology, rare disease, hematology, immunology, cardiovascular, metabolic, and beyond calling on accounts shaped by forces and characterized by nuances that pre-call plans rarely account for, including integrated delivery networks, value-based contracts, electronic health record protocols, and patient access programs. While pharma sales forces are charged with demand generation and differentiation, their effectiveness can be greatly enhanced through an account management mindset. The problem isn’t that reps are unable to adopt an account mindset it is that in many instances they haven’t been asked to.
An account management mindset entails understanding account context across clinical, financial and operational lenses, organization priorities, and decision-making dynamics, all of which influence how HCP prescribers think about new medicines and treatments in patient care. It requires reps to look beyond the HCP and instead interpret how systems, pathways, policies, and internal colleagues influence access, prescribing, and patient care. In short, it is the mindset shift from ‘planning a call’ to ‘understanding the account’ so that meaningful progress within increasingly complex, and more prevalent system-driven environments can be made.
What changes when reps adopt an account engagement mindset
The shift is straightforward to describe but potentially more difficult to operationalize. Before a rep plans a customer call, the rep needs to have is a more comprehensive understanding of the account.
That means knowing answers to questions most reps traditionally were never trained to ask, including:
- What kind of account is this: independent practice, system-affiliated, IDN-owned, or academic?
- Who really controls what gets prescribed and reimbursed? Is the decision a local, regional, or system-level one?
- What protocols, pathways, or formulary positions already shape what the HCP can do?
- What is the account trying to accomplish this year (e.g., cost, quality, access, growth), and where does the product fit with that agenda?
- Maybe most importantly, who else from my company is calling on this account, and what are they working on? How am I working with my account or matrix team partners to further the account and the company’s objectives?
This does not replace pre-call planning; it reframes it. When reps enter a call with this broader context, the conversation changes immediately. Instead of leading with a product pitch, they can ask thoughtful questions that matter to the HCP. Objections shift from product features to real-world access challenges. The rep becomes part of the broader account team rather than acting as a single point of contact.
Why this matters for commercial leaders
For Chief Commercial Officers, VPs of Commercial Excellence, Market Access leaders, Heads of Sales and Training, this has become a capability issue, not a content question. Reps can be provided with up-to-date account profiles, system maps, and metric-heavy CRM dashboards, but data without the proper mindset tends to produce the same account call plans dressed up as new slides.
Now, the capability requiring strengthening and incentivizing is interpretive in nature. Upskilling reps to be able to read all the nuances of an account, compliantly solicit input from their account team members, and form a robust data-driven point of view about what matters, is now a necessity. Such an approach will help inform and shape impactful downstream account decisions, including which HCPs to call on, which messages to lead with, which colleagues to pull in, and which conversations are worth having, all will require more than a single visit.
This capability will not be honed after a single training module. It develops through consistent, deliberate practice, coaching in the field, and reinforcement from commercial leadership who model the behavior in their own account reviews.
The competitive consequence
Companies that have been building an account management capability across their sales organizations, not just inside their Key Account Manager teams, are outperforming their competitors. Their reps are more attuned to account dynamics, enabling more integrated cross-functional engagement with key stakeholders. Launches tend to land and track faster because field teams have a more robust understanding of pathways and access challenges from the outset. As important, commercial leaders are positioned to render sharper resource decisions because the field is continuously generating account insights, not just call activity metrics.
Companies that fail to make this shift in account engagement perspective and commensurate skill building will find their reps working harder to produce less. Yes, the pre-call plan will still be executed. Yes, the call will still be placed. But the account will keep moving without them.
The message is clear. The starting line for biopharma ‘selling’ has moved. The question for commercial leaders, now, is whether they will enable and equip their field forces to move with it.
